6533b86efe1ef96bd12cc7f6

RESEARCH PRODUCT

Prognostic significance of spatial and density analysis of T lymphocytes in colorectal cancer.

Hanna ElomaaMaarit AhtiainenSara A. VäyrynenShuji OginoJonathan A. NowakMarjukka FrimanOlli HelminenErkki Ville WirtaToni T. SeppäläJan BöhmMarkus J. MäkinenJukka-pekka MecklinTeijo KuopioJuha P. Väyrynen

subject

Cancer ResearchkasvaimetIDENTIFICATIONtumour immunologyT-LymphocytesBIOMARKERS3122 Cancerscolorectal cancerCD8-Positive T-Lymphocytes3126 Surgery anesthesiology intensive care radiologyPrognosisT-imusolutimmunohistokemiaLymphocytes Tumor-InfiltratingOncologyBRAF MUTATIONBiomarkers TumorHumanssyöpätauditLymphocyte CountColorectal NeoplasmsIMMUNOSCOREcancer microenvironmentpaksusuolisyöpä

description

Abstract Background Although high T cell density is a strong favourable prognostic factor in colorectal cancer, the significance of the spatial distribution of T cells is incompletely understood. We aimed to evaluate the prognostic significance of tumour cell-T cell co-localisation and T cell densities. Methods We analysed CD3 and CD8 immunohistochemistry in a study cohort of 983 colorectal cancer patients and a validation cohort (N = 246). Individual immune and tumour cells were identified to calculate T cell densities (to derive T cell density score) and G-cross function values, estimating the likelihood of tumour cells being co-located with T cells within 20 µm radius (to derive T cell proximity score). Results High T cell proximity score associated with longer cancer-specific survival in both the study cohort [adjusted HR for high (vs. low) 0.33, 95% CI 0.20–0.52, Ptrend < 0.0001] and the validation cohort [adjusted HR for high (vs. low) 0.15, 95% CI 0.05–0.45, Ptrend < 0.0001] and its prognostic value was independent of T cell density score. Conclusions The spatial point pattern analysis of tumour cell-T cell co-localisation could provide detailed information on colorectal cancer prognosis, supporting the value of spatial measurement of T cell infiltrates as a novel, robust tumour-immune biomarker.

10.3390/jcm10081751https://pubmed.ncbi.nlm.nih.gov/35449453